Title:
DRUG FOR TREATMENT OF BREAST CANCER AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/065243
Kind Code:
A1
Abstract:
Provided herein is an application of an anti-PS antibody in combination with docetaxel and/or paclitaxel in a drug for the treatment of a breast cancer, belonging to the technical field of drugs. By means of the combination of the anti-PS antibody and docetaxel and/or paclitaxel, an expression phenotype of ATP11B low/Ptdss2 high is changed to the ATP11B high/Ptdss2 low to effectively overcome the metastasis process, which can not only reduce a primary tumor, but also greatly inhibit the metastasis of the primary tumor. Therefore, a new selective therapeutic strategy and drug are provided to prevent and treat breast cancers and their metastasis.
Inventors:
XU XIAOLING (CN)
XU JUN (CN)
DENG CHUXIA (CN)
XU JUN (CN)
DENG CHUXIA (CN)
Application Number:
PCT/CN2022/121991
Publication Date:
April 04, 2024
Filing Date:
September 28, 2022
Export Citation:
Assignee:
UNIV MACAU (CN)
International Classes:
C07K16/28; A61K31/337; A61K33/243; A61P35/00
Domestic Patent References:
| WO2018064013A1 | 2018-04-05 |
Other References:
RAGHUNADHARAO DIGUMARTI: "Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer", LUNG CANCER., ELSEVIER, AMSTERDAM., NL, vol. 86, no. 2, 1 November 2014 (2014-11-01), NL , pages 231 - 236, XP093152228, ISSN: 0169-5002, DOI: 10.1016/j.lungcan.2014.08.010
TIWARI SHRUTI R.; MISHRA PRASUN; RASKA PAOLA; CALHOUN BENJAMIN; ABRAHAM JAME; MOORE HALLE; BUDD G. THOMAS; FANNING ALICIA; VALENTE: "Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer", BREAST CANCER RESEARCH AND TREATMENT, SPRINGER US, NEW YORK, vol. 158, no. 1, 20 June 2016 (2016-06-20), New York, pages 189 - 193, XP035996374, ISSN: 0167-6806, DOI: 10.1007/s10549-016-3866-0
KAREN BULLOCK: "Clinical Efficacy of Taxane–Trastuzumab Combination Regimens for HER-2–Positive Metastatic Breast Cancer", THE ONCOLOGIST, vol. 13, no. 5, 1 May 2008 (2008-05-01), pages 515 - 525, XP093152230, ISSN: 1083-7159, DOI: 10.1634/theoncologist.2007-0204
MICHAEL J. GRAY, JIAN GONG, MICHAELA M. S. HATCH, VAN NGUYEN, CHRISTOPHER C. W. HUGHES, JEFF T. HUTCHINS, BRUCE D. FREIMARK: "Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers", BREAST CANCER RESEARCH, CURRENT MEDICINE GROUP LTD., GB, vol. 18, no. 1, 1 December 2016 (2016-12-01), GB , pages 50 - 50, XP055430724, ISSN: 1465-5411, DOI: 10.1186/s13058-016-0708-2
GIOVANNA GARUFI: "Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors", EXPERT OPIN PHARMACOTHER, ASHLEY PUBLICATIONS LTD, LONDON, UK, vol. 21, no. 6, 12 April 2020 (2020-04-12), London, UK , pages 687 - 699, XP093152229, ISSN: 1465-6566, DOI: 10.1080/14656566.2020.1724957
TIWARI SHRUTI R.; MISHRA PRASUN; RASKA PAOLA; CALHOUN BENJAMIN; ABRAHAM JAME; MOORE HALLE; BUDD G. THOMAS; FANNING ALICIA; VALENTE: "Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer", BREAST CANCER RESEARCH AND TREATMENT, SPRINGER US, NEW YORK, vol. 158, no. 1, 20 June 2016 (2016-06-20), New York, pages 189 - 193, XP035996374, ISSN: 0167-6806, DOI: 10.1007/s10549-016-3866-0
KAREN BULLOCK: "Clinical Efficacy of Taxane–Trastuzumab Combination Regimens for HER-2–Positive Metastatic Breast Cancer", THE ONCOLOGIST, vol. 13, no. 5, 1 May 2008 (2008-05-01), pages 515 - 525, XP093152230, ISSN: 1083-7159, DOI: 10.1634/theoncologist.2007-0204
MICHAEL J. GRAY, JIAN GONG, MICHAELA M. S. HATCH, VAN NGUYEN, CHRISTOPHER C. W. HUGHES, JEFF T. HUTCHINS, BRUCE D. FREIMARK: "Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers", BREAST CANCER RESEARCH, CURRENT MEDICINE GROUP LTD., GB, vol. 18, no. 1, 1 December 2016 (2016-12-01), GB , pages 50 - 50, XP055430724, ISSN: 1465-5411, DOI: 10.1186/s13058-016-0708-2
GIOVANNA GARUFI: "Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors", EXPERT OPIN PHARMACOTHER, ASHLEY PUBLICATIONS LTD, LONDON, UK, vol. 21, no. 6, 12 April 2020 (2020-04-12), London, UK , pages 687 - 699, XP093152229, ISSN: 1465-6566, DOI: 10.1080/14656566.2020.1724957
Attorney, Agent or Firm:
BORSAM INTELLECTUAL PROPERTY LTD. (CN)
Download PDF:
Previous Patent: CAPABILITY FOR LOGICAL RESOURCE FOR BEAM MANAGEMENT
Next Patent: INTER-USER EQUIPMENT COORDINATION IN SIDELINK
Next Patent: INTER-USER EQUIPMENT COORDINATION IN SIDELINK